Claim your 20% discount on Global Market Reports with code ONLINE20. Limited time only.
What Is The Present And Forecasted Size Of The Unresectable Hepatocellular Carcinoma Market?
Recent years have seen a slight increase in the market size for unresectable hepatocellular carcinoma. This growth is projected to continue, with the market expanding from $1.98 billion in 2024 to $2.01 billion in 2025. This represents a compound annual growth rate (CAGR) of 1.5%. Factors contributing to this growth include advancements in chemotherapy, results of clinical trials, limitations in liver transplantation, a rise in cancer diagnoses, and wider access to treatments.
Anticipations suggest robust expansion in the market size of unresectable hepatocellular carcinoma in the forthcoming years. The market is projected to swell to a value of $2.93 billion by 2029, boasting a compound annual growth rate (CAGR) of 9.9%. Factors driving the growth during this period involve modifications in healthcare policies, the use of strategies for patient stratification, implementation of real-world evidence, boosted patient advocacy and awareness, and fluctuating economics. The forecast period is likely to witness key trends such as precision medicine and biomarkers, integration of real-world evidence and data, adoption of multidisciplinary approaches, initiation of global clinical trials and collaborations, along with an emphasis on patient-centric care.
Get A Free Sample Of The Report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12079&type=smp
What Drivers Are Accelerating Expansion Of The Unresectable Hepatocellular Carcinoma Market?
The rise in liver cancer cases is propelling the growth of the unresectable hepatocellular carcinoma market. This form of cancer is characterized by tumor cells aggressively replacing the healthy, functioning liver cells. The standard treatments for unresectable hepatocellular carcinoma include liver transplantation and radiofrequency ablation. For instance, a peer-reviewed scientific journal based in Switzerland, the Journal of Hepatology, reported in October 2022 that liver cancer had been the cause of death for 830,200 individuals worldwide by 2020. The report further projected an increase of 55.0% in new liver cancer cases between 2020 and 2040, amounting to an estimated 1.4 million new cases. Moreover, the American Cancer Society, a US-based non-profit organization, estimated in January 2024 that there would be about 41,630 new cases of primary liver cancer and intrahepatic bile duct cancer in the U.S. in 2024, predicting 29,840 deaths (19,120 men and 10,720 women) resulting from these diseases. Consequently, the escalating prevalence of liver cancer is fueling the growth of the unresectable hepatocellular carcinoma market.
What Are The Primary Segmentation Parameters In The Unresectable Hepatocellular Carcinoma Market?
The unresectable hepatocellular carcinomamarket covered in this report is segmented –
1) By Type: Primary; Secondary; Benign Liver Growth
2) By Treatment Type: Chemotherapy; Molecularly Targeted Therapy; Immunotherapy; Other Treatments
3) By End-Users: Hospitals; Specialty Clinics; Cancer Centers
Subsegments:
1) By Primary: Hepatocellular Carcinoma (HCC); Fibrolamellar Carcinoma; Hepatoblastoma
2) By Secondary: Metastatic Liver Cancer; Intrahepatic Cholangiocarcinoma
3) By Benign Liver Growth: Hepatic Adenoma; Focal Nodular Hyperplasia; Hemangiomas
How Are Industry Trends Steering The Expansion Of The Unresectable Hepatocellular Carcinoma Market?
The rise of innovative products is a significant trend being observed in the market for unresectable hepatocellular carcinoma. To remain competitive, leading companies within the market are implementing product innovation strategies. For example, in October 2022, AstraZeneca, a company specializing in pharmaceuticals and biotechnology in the UK, introduced the FDA-endorsed medication Imjudo (tremelimumab), to be used with Imfinzi, for patients in the US with inoperable liver cancer. Known as the STRIDE regimen (Single Tremelimumab Regular Interval Durvalumab), this latest treatment involves a singular dosage of the anti-CTLA-4 antibody Imjudo 300mg together with the anti-PD-L1 antibody Imfinzi 1500 mg every month. The risk of fatality was found to be 22% less in patients who were administered Imjudo and Imfinzi in unison, compared to those given sorafenib.
Which Players Are Shaping The Competitive Landscape Of The Unresectable Hepatocellular Carcinoma Market?
Major companies operating in the unresectable hepatocellular carcinoma market include Pfizer Inc., Johnson & Johnson Private Limited, F Hoffmann-La Roche Ltd., Merck & Co Inc., Bayer AG, Bristol-Myers-Squibb Company, Astrazeneca PLC, Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Regeneron Pharmaceuticals Inc., Chugai Pharmaceutical Co Ltd., Eisai Co. Ltd., Ipsen S.A., Jiangsu HengRui Medicine Co. Ltd., Exelixis Inc., BeiGene Ltd., Halozyme Therapeutics Inc., Innovent Biologics Inc., Sirtex Medical Limited, Blueprint Medicines Corporation, Genentech Inc., CStone Pharmaceuticals, Pharmicell Co. Ltd., Pharmaxis Ltd., Delcath Systems Inc., Yiviva Inc., Celsion Corporation, Mendus AB.
Access The Complete Report Here:
What Are The Emerging Regional Trends Driving The Unresectable Hepatocellular Carcinoma Market?
North America was the largest region in the unresectable hepatocellular carcinoma market in 2024. The regions covered in the unresectable hepatocellular carcinoma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Customize Your Report Here:
https://www.thebusinessresearchcompany.com/customise?id=12079&type=smp
Browse Through More Reports Similar to the Global Unresectable Hepatocellular Carcinoma Market 2025, By The Business Research Company
Pain Management Devices And Therapies Global Market Report 2025
Metabolomics Global Market Report 2025
https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report
Isothermal Nucleic Acid Amplification Technology Global Market Report 2025
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model